FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002160125> ?p ?o ?g. }

• W2002160125 endingPage "1202" @default.
• W2002160125 startingPage "1188" @default.
• W2002160125 abstract "Recently, we observed that suppression of tumor xenograft growth by silibinin was associated with reduction in tumor vasculature and an increased apoptosis. Here, we provide evidence for molecular events associated with antiangiogenic efficacy of pharmacologically achievable doses of silibinin in endothelial cell culture system. Our data show that silibinin almost completely (P<0.001) inhibits growth of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC-dermal origin) together with induction of cell death in a dose- and time-dependent manner. Growth inhibition was associated with a strong induction of G1 arrest accompanied by an increase in Kip1/p27, Cip1/p21 and p53. Apoptosis induction (up to 14- to 17-fold in both cell lines, P<0.001) was an underlying mechanism in silibinin-induced death of endothelial cells. In the studies elucidating the molecular events involved in apoptosis, silibinin caused loss of mitochondrial membrane potential and an increase in cytochrome c release from mitochondria. An increase in Bax and a decrease in Mcl-1 proteins were also observed. Silibinin-induced apoptosis involved both caspase-dependent and -independent mechanisms. Silibinin also decreased survivin level and inhibited Akt and NF-κB signaling. Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-κB. Further, silibinin showed a concentration-dependent strong inhibition of capillary tube formation on matrigel, retraction and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC. Together, these findings identify pleiotropic mechanisms for antiangiogenic efficacy of silibinin, and suggest its usefulness in angioprevention and antiangiogenic therapy." @default.
• W2002160125 created "2016-06-24" @default.
• W2002160125 creator A5027734680 @default.
• W2002160125 creator A5043552005 @default.
• W2002160125 creator A5048444823 @default.
• W2002160125 creator A5084515109 @default.
• W2002160125 date "2004-11-22" @default.
• W2002160125 modified "2023-10-12" @default.
• W2002160125 title "Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy" @default.
• W2002160125 cites W106047730 @default.
• W2002160125 cites W1495287184 @default.
• W2002160125 cites W1500624186 @default.
• W2002160125 cites W1510237891 @default.
• W2002160125 cites W1562884473 @default.
• W2002160125 cites W1564674105 @default.
• W2002160125 cites W1573363574 @default.
• W2002160125 cites W1579297325 @default.
• W2002160125 cites W1598952686 @default.
• W2002160125 cites W1617532721 @default.
• W2002160125 cites W1641228030 @default.
• W2002160125 cites W1797700808 @default.
• W2002160125 cites W1968262266 @default.
• W2002160125 cites W1969328947 @default.
• W2002160125 cites W1972623336 @default.
• W2002160125 cites W1979215811 @default.
• W2002160125 cites W1982621844 @default.
• W2002160125 cites W1984614875 @default.
• W2002160125 cites W1989565001 @default.
• W2002160125 cites W1997733193 @default.
• W2002160125 cites W1999600810 @default.
• W2002160125 cites W2010987628 @default.
• W2002160125 cites W2020316909 @default.
• W2002160125 cites W2024587123 @default.
• W2002160125 cites W2026036357 @default.
• W2002160125 cites W2026106245 @default.
• W2002160125 cites W2027671289 @default.
• W2002160125 cites W2028501194 @default.
• W2002160125 cites W2030877711 @default.
• W2002160125 cites W2032350328 @default.
• W2002160125 cites W2038784909 @default.
• W2002160125 cites W2039791984 @default.
• W2002160125 cites W2040470926 @default.
• W2002160125 cites W2044258256 @default.
• W2002160125 cites W2049053145 @default.
• W2002160125 cites W2049856484 @default.
• W2002160125 cites W2056962024 @default.
• W2002160125 cites W2060105570 @default.
• W2002160125 cites W2064580048 @default.
• W2002160125 cites W2070061120 @default.
• W2002160125 cites W2072252062 @default.
• W2002160125 cites W2072259101 @default.
• W2002160125 cites W2084796179 @default.
• W2002160125 cites W2086189875 @default.
• W2002160125 cites W2089808128 @default.
• W2002160125 cites W2094420450 @default.
• W2002160125 cites W2102950926 @default.
• W2002160125 cites W2113999599 @default.
• W2002160125 cites W2119683782 @default.
• W2002160125 cites W2125941855 @default.
• W2002160125 cites W2132411546 @default.
• W2002160125 cites W2143629217 @default.
• W2002160125 cites W2146916102 @default.
• W2002160125 cites W2150048971 @default.
• W2002160125 cites W2150476216 @default.
• W2002160125 cites W2160307820 @default.
• W2002160125 cites W2163453798 @default.
• W2002160125 cites W2166655452 @default.
• W2002160125 cites W2166781237 @default.
• W2002160125 doi "https://doi.org/10.1038/sj.onc.1208276" @default.
• W2002160125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15558015" @default.
• W2002160125 hasPublicationYear "2004" @default.
• W2002160125 type Work @default.
• W2002160125 sameAs 2002160125 @default.
• W2002160125 citedByCount "134" @default.
• W2002160125 countsByYear W20021601252012 @default.
• W2002160125 countsByYear W20021601252013 @default.
• W2002160125 countsByYear W20021601252014 @default.
• W2002160125 countsByYear W20021601252015 @default.
• W2002160125 countsByYear W20021601252016 @default.
• W2002160125 countsByYear W20021601252017 @default.
• W2002160125 countsByYear W20021601252018 @default.
• W2002160125 countsByYear W20021601252019 @default.
• W2002160125 countsByYear W20021601252020 @default.
• W2002160125 countsByYear W20021601252021 @default.
• W2002160125 countsByYear W20021601252022 @default.
• W2002160125 crossrefType "journal-article" @default.
• W2002160125 hasAuthorship W2002160125A5027734680 @default.
• W2002160125 hasAuthorship W2002160125A5043552005 @default.
• W2002160125 hasAuthorship W2002160125A5048444823 @default.
• W2002160125 hasAuthorship W2002160125A5084515109 @default.
• W2002160125 hasBestOaLocation W20021601251 @default.
• W2002160125 hasConcept C123012128 @default.
• W2002160125 hasConcept C190283241 @default.
• W2002160125 hasConcept C202751555 @default.
• W2002160125 hasConcept C2775975398 @default.
• W2002160125 hasConcept C2776912716 @default.
• W2002160125 hasConcept C2777130413 @default.
• W2002160125 hasConcept C2777834122 @default.

• next